5-aminolevulinic acid derivatives, methods for their preparation and uses thereof
US-9018257-B2 · Apr 28, 2015 · US
Erythropoietin production-promoting agent
US9469598B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9469598-B2 |
| Application number | US-201214350522-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 5, 2012 |
| Priority date | Oct 12, 2011 |
| Publication date | Oct 18, 2016 |
| Grant date | Oct 18, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A therapeutic and/or prophylactic agent for renal anemia comprising ALAs and an erythropoietin production promoter comprising ALAs.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for promoting production of erythropoietin, comprising: administering to a subject with reduced erythropoietin production a therapeutically effective amount of a compound shown by the following Formula (I): R 1 —NHCH 2 COCH 2 CH 2 COOR 2 (I) wherein R 1 represents a hydrogen atom, and R 2 represents a hydrogen atom, or a salt thereof. 2. A method for treating anemia arising from reduction of erythropoietin production, comprising: administering to a subject with anemia arising from reduction of erythropoietin production an agent comprising a therapeutically effective amount of a compound shown by the following Formula (I): R 1 —NHCH 2 COCH 2 CH 2 COOR 2 (I) wherein R 1 represents a hydrogen atom, and R 2 represents a hydrogen atom, or a salt thereof. 3. The method according to claim 2 , characterized in that said agent further contains one or more metal-containing compounds. 4. The method according to claim 3 , characterized in that said metal-containing compound is a compound containing a metal selected from the group consisting of iron, and zinc. 5. The method according to claim 3 , characterized in that said metal compound is a compound containing iron. 6. The method according to claim 2 characterized in that said reduction of erythropoietin production is caused by inflammatory cytokine or uremic toxin. 7. The method according to claim 2 , characterized in that said anemia is renal anemia. 8. The method according to claim 7 , characterized in that said compound or a salt thereof promotes the production of erythropoietin. 9. The method according to claim 2 , characterized in that said agent further contains one or more metal-containing compounds. 10. The method according to claim 2 , characterized in that said anemia is renal anemia. 11. The method according to claim 3 , characterized in that said anemia is renal anemia. 12. The method according to claim 4 , characterized in that said anemia is renal anemia. 13. The method according to claim 5 , characterized in that said anemia is renal anemia. 14. The method according to claim 6 , characterized in that said anemia is renal anemia.
Assignees
Inventors
Classifications
Antianaemics · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
- C07C217/08Primary
the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom · CPC title
Zinc; Compounds thereof · CPC title
- A61K31/197Primary
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9469598B2 cover?
- A therapeutic and/or prophylactic agent for renal anemia comprising ALAs and an erythropoietin production promoter comprising ALAs.
- Who is the assignee on this patent?
- Sbi Pharmaceuticals Co Ltd, Tohuku Univ, Univ Tohoku
- What technology area does this patent fall under?
- Primary CPC classification C07C217/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).